AU2016258084B2 - Use of CD24 for lowering low-density lipoprotein cholesterol levels - Google Patents

Use of CD24 for lowering low-density lipoprotein cholesterol levels Download PDF

Info

Publication number
AU2016258084B2
AU2016258084B2 AU2016258084A AU2016258084A AU2016258084B2 AU 2016258084 B2 AU2016258084 B2 AU 2016258084B2 AU 2016258084 A AU2016258084 A AU 2016258084A AU 2016258084 A AU2016258084 A AU 2016258084A AU 2016258084 B2 AU2016258084 B2 AU 2016258084B2
Authority
AU
Australia
Prior art keywords
protein
subject
ldl
mins
cd24fc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016258084A
Other languages
English (en)
Other versions
AU2016258084A1 (en
Inventor
Yang Liu
Pan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OncoImmune Inc
Original Assignee
OncoImmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoImmune Inc filed Critical OncoImmune Inc
Publication of AU2016258084A1 publication Critical patent/AU2016258084A1/en
Application granted granted Critical
Publication of AU2016258084B2 publication Critical patent/AU2016258084B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
AU2016258084A 2015-05-07 2016-05-06 Use of CD24 for lowering low-density lipoprotein cholesterol levels Ceased AU2016258084B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
US62/158,157 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (2)

Publication Number Publication Date
AU2016258084A1 AU2016258084A1 (en) 2017-11-02
AU2016258084B2 true AU2016258084B2 (en) 2020-01-30

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016258084A Ceased AU2016258084B2 (en) 2015-05-07 2016-05-06 Use of CD24 for lowering low-density lipoprotein cholesterol levels

Country Status (18)

Country Link
US (2) US10369197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3292144B1 (cg-RX-API-DMAC7.html)
JP (1) JP6751756B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170141216A (cg-RX-API-DMAC7.html)
CN (1) CN107531772B (cg-RX-API-DMAC7.html)
AU (1) AU2016258084B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017022394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982612A1 (cg-RX-API-DMAC7.html)
EA (1) EA038520B1 (cg-RX-API-DMAC7.html)
ES (1) ES2829235T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249521A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20201651T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051866T2 (cg-RX-API-DMAC7.html)
IL (1) IL255086B (cg-RX-API-DMAC7.html)
MX (1) MX385941B (cg-RX-API-DMAC7.html)
PT (1) PT3292144T (cg-RX-API-DMAC7.html)
WO (1) WO2016179456A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706846B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
TW202015753A (zh) * 2018-06-04 2020-05-01 美商昂科免疫公司 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
US20230103352A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010029248A1 (en) * 1999-04-23 2001-10-11 Protein Technologies International, Inc. Composition for and method of reducing low density lipoprotein cholesterol concentration
US20110002846A1 (en) * 2007-12-21 2011-01-06 Univeristy of Rochester Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain
US20110142913A1 (en) * 2009-12-10 2011-06-16 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20130136739A1 (en) * 2010-04-28 2013-05-30 Oncoimmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US20140357505A1 (en) * 2011-06-10 2014-12-04 The Trustees Of The University Of Pennsylvania System And Method Of Cytomic Vascular Health Profiling
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010029248A1 (en) * 1999-04-23 2001-10-11 Protein Technologies International, Inc. Composition for and method of reducing low density lipoprotein cholesterol concentration
US20110002846A1 (en) * 2007-12-21 2011-01-06 Univeristy of Rochester Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain
US20110142913A1 (en) * 2009-12-10 2011-06-16 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20130136739A1 (en) * 2010-04-28 2013-05-30 Oncoimmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Also Published As

Publication number Publication date
ES2829235T3 (es) 2021-05-31
JP2018515605A (ja) 2018-06-14
ZA201706846B (en) 2018-12-19
EP3292144A1 (en) 2018-03-14
CN107531772A (zh) 2018-01-02
EP3292144B1 (en) 2020-08-26
PT3292144T (pt) 2020-11-05
WO2016179456A1 (en) 2016-11-10
HRP20201651T1 (hr) 2020-12-25
US10369197B2 (en) 2019-08-06
HK1249521A1 (zh) 2018-11-02
AU2016258084A1 (en) 2017-11-02
CN107531772B (zh) 2021-09-21
EA038520B1 (ru) 2021-09-09
EP3292144A4 (en) 2018-11-14
US11026995B2 (en) 2021-06-08
US20190307841A1 (en) 2019-10-10
JP6751756B2 (ja) 2020-09-09
MX385941B (es) 2025-03-18
IL255086A0 (en) 2017-12-31
HUE051866T2 (hu) 2021-03-29
BR112017022394A2 (pt) 2018-07-17
KR20170141216A (ko) 2017-12-22
CA2982612A1 (en) 2016-11-10
MX2017014095A (es) 2018-03-16
IL255086B (en) 2021-08-31
EA201792418A1 (ru) 2018-02-28
US20180110828A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
EP3292144A4 (en) Use of cd24 for lowering low-density lipoprotein cholesterol levels
EP3123804A4 (en) Mechanisms of virtual clear channel assessment for wi-fi devices
EP3354045A4 (en) APPARATUS FOR CAPTURING THE MOVEMENTS OF THE DIFFERENTIAL HEAD
EP3205220A4 (en) New type of air-flow preheating device
EP3177924A4 (en) Stabilization of whole blood samples
EP3162359A4 (en) Oil-in-water emulsion composition
EP3139064A4 (en) Damper apparatus
EP3212315A4 (en) Compositions and methods for forming emulsions
EP3121262A4 (en) Examination apparatus
EP3200802A4 (en) Compositions and methods for maintaining cognitive function
EP3209673A4 (en) MIXTURES OF HMOs
EP3187181A4 (en) Emulsion composition
EP3244069A4 (en) Construction apparatus
EP3398517A4 (en) RADIOGRAPHY APPARATUS
EP2987710A3 (de) Universalhalter
EP3229809A4 (en) Compounds and methods involving sterols
EP3174525A4 (en) Otic formulations for the treatment of ceruminosis
EP3093615A4 (en) Level for checking inclination of structure
EP3095439A4 (en) Emulsion composition for skin
EP3262333B8 (de) Rotations-stabilisierungseinrichtung
EP3146391A4 (en) Developing apparatus
EP3095923A4 (en) Handrail for construction equipment
EP3203992A4 (en) Compositions and methods for increasing the bioavailability of one or more compounds
EP3210927A4 (en) Elevator apparatus
EP3351179A4 (en) Radiography apparatus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired